

Slide 1	Evidence-Based Infection Control Mark Loeb MD, MSc McMaster University loebm@mcmaster.ca Hosted by Paul Webber Paul@webbertraining.com A Webber Training Teleclass	
Slide 2	Definition Evidence-based infection control isthe explicit, judicious and conscientious use of current best evidence from infection control research in making decisions about the prevention and control of infection of individuals and populations.	
Slide 3	Evidence-based infection controlis an attempt to build a bridge between evidence from research and infection control practice.	

A Webber Training Teleclass with Dr. Mark Loeb


Slide 4



Slide 5




Slide 6



A Webber Training Teleclass with Dr. Mark Loeb

Slide 7



Slide 8

5 Steps of Evidence-Based Infection Control

- Framing the question appropriate to the circumstances
- · Finding the evidence
- · Evaluating the evidence
- · Making and doing the decision
- · Evaluating the process



A Webber Training Teleclass with Dr. Mark Loeb

Slide 10



~1		1	-	4
∨ ।	1	പപ	- 1	- 1
וכי	ш	de	1	1

Framing the question

PICO

- · Patient or Population
- Intervention
- Comparison
- Outcome

lic		

Framing the Question

In nurses providing care to SARS patients in the ICU, does use of an N95 mask reduce SARS transmission?

G1: 1 4 6		
Slide 13	5 Steps of EBIC □framing the question √finding the evidence □evaluation of the evidence □making and doing the decision □evaluation of the whole process	
Slide 14		
Shac T	Approach to Research Evidence: What question am I asking? •Therapy •Prognosis •Diagnosis •Etiology	
Slide 15	Common features of Infection Control Research 1.Comparative	
	Soap 1 vs Soap 2 MRSA culture vs PCR N95 vs No N95	

A Webber Training Teleclass with Dr. Mark Loeb


α			4	_
~	14	$^{\circ}$		4
1	lid	_		()

Common features (con't)

- 2. Preplanned
- •Objective,rationale,background
- •Inclusion and exclusion criteria
- Methodology for all interventions
- •Outcomes and how&when measured

Slide 17

Severe Acute Respiratory Syndrome (SARS)



March 25, 2003

April 2, 2003

Slide 18

Question


In patients with SARS, does interferon reduce mortality?


A Webber Training Teleclass with Dr. Mark Loeb

α			-1	
· '	110	\sim	- 1	
S	110	ı	- 1	9

Levels of Evidence	
•Animal study •Case Report •Case-control	
•Cohort •RCT •Systematic review	

Slide 20





Hosted by Paul Webber	paul@webbertraining.com
Sponsored by Webber Train	ing www.webbertraining.com

A Webber Training Teleclass with Dr. Mark Loeb

Slide 22

Case-Control Study

- ·Begin with Case
- Compare to controls
- Pros: quick, inexpensive
- Cons: bias in selection of cases, selection of controls, recall bias,measurement
- •Use: determine risk

~1		1		_	^
V 1	1	А.	\sim	٠,	' 2
Sl	ш	u		2	_)

Cohort Study

- •Begin with patients who do NOT have the outcome
- •Follow forward in time
- •Pros: less bias since outcome unknown, better to design data collection
- •Con: expensive,lengthy
- •Use: best to assess risk,outcome

Slide 24

Randomized Controlled Trials

- •Randomly allocate patients to an intervention, follow up and measure outcomes
- •Pro: reduce selection, assessment
- bias, confounding
- ·Con: expensive, not always possible
- Bottom line: gold standard for prevention, treatment


A Webber Training Teleclass with Dr. Mark Loeb

Slide 25

Systematic review

- ·Highest form of evidence
- •Evidence-based review article
- ·Has purpose, search strategy, inclusion and exclusion criteria
- ·May or may not include metaanalysis
- •Bottom line: summary of the best evidence

Slide 26



Slide 27

JASPA


(Journal Associated Score of Personal Angst)

- J: Are you ambivalent about renewing your JOURNAL subscriptions?
- A: Do you feel ANGER towards prolific authors?
- S: Do you ever use journals to help you SLEEP?
- P: Are you surrounded by PILES of PERIODICALS? A: Do you feel ANXIOUS when journals arrive?
 - liar?
 - normal range sick


 - * Modified from: BMJ 1995;311:1666-1668


A Webber Training Teleclass with Dr. Mark Loeb

Slide 28




Slide 29






A Webber Training Teleclass with Dr. Mark Loeb

Slide 31




Slide 32





A Webber Training Teleclass with Dr. Mark Loeb


Slide 34



Slide 35



Slide 36




A Webber Training Teleclass with Dr. Mark Loeb

Slide 37



Slide 38



Slide 39

5 Steps of EBIC
□framing the question
□finding the evidence
✓ evaluation of the evidence
□making and doing the decision
□evaluation of the whole process

Slide 40	Preventive or Therapeutic Trial: Are the results valid? •Was assignment of treatment randomized? •Was the randomization list concealed? •Were all patients who entered the trial accounted for at the end? •Were they analyzed in the groups to which they were randomized?	
Slide 41	Preventive or Therapeutic Trial: Are the results valid? •Was there "blinding"? If so who was blinded? •Were the groups treated equally (aside from experimental intervention)? •Were the groups similar at the start of the trial?	
Slide 42	Preventive or Therapeutic Trial: What are the results? •How large is the treatment effect? •How precise is the treatment effect?	

01: 1 40		1
Slide 43	Risk Reduction	
	Absolute risk reduction = control rate - experimental rate	
	Relative risk reduction = <u>control rate - experimental rate</u>	
	control rate	
Slide 44		1
Silde 44	Drug A: 2% die of pneumonia Placebo: 4% die of pneumonia	
	Absolute difference: 4% - 2% = 2%	
	Relative difference: 4%-2% = 50% 4%	
Slide 45		1
Siluc 43	Number Needed to Treat (NNT)	
	Number of patients who need to be treated to prevent 1 or more	
	adverse events	
	NNT = 1/ARR e.g. 1/0.02 = 50	

A Webber Training Teleclass with Dr. Mark Loeb

Slide 46

Confidence Intervals

- A way of quantifying the uncertainty in measurement
- 95% CI = range of values within which we can be 95% sure that the true value for the whole population lies

RR = 1.3 (95% CI, 1.02 - 1.74)

Slide 47

Preventive or Therapeutic Trial: Will the results help me provide healthcare?

•Can the results be applied to my patient population?

•Were all important outcomes considered?



	L'idence Dasca III	eetion control
	A Webber Training Teleclar	ss with Dr. Mark Loeb
Slide 49	Prognosis Study: Are the results valid? •Was a representative and well-designed sample of patients collected at a similar point in the course of their disease (condition)? •Was follow up sufficiently long and complete? •Were objective and unbiased outcome criteria used? •Was adjustment for important prognostic factors done?	
Slide 50	Systematic review: Are the results valid? •Does the stated objective of the review address your question? •Does the methods section describe finding and including all relevent studies? •Is study validity assessed? •Are the results consistent from study to study?	
Slide 51	Systematic Reviews: What are the results? •How large is the treatment effect? •How precise is the treatment effect?	

A Webber Training Teleclass with Dr. Mark Loeb

Slide 52

Systematic Reviews: Will the results help me provide healthcare?

- •Can the results be applied to my patient population?
- •Were all important outcomes considered? •Are the likely benefits worth the potential harms and benefits?

α	•	1	
~	1.	de	54
N)	П	uu	ככ